HOTLINE: Effective November 15, 2021

0098833 **Olanzapine** **OLANZ**

Performed: Tues, Fri
Reported: 1-7 days

Specimen Required: Patient Prep: Timing of specimen collection: Pre-dose (trough) draw - At steady state concentration.
Collect: Plain red. Also acceptable: Lavender (K_2 or K_3EDTA) or pink (K_2EDTA).
Specimen Preparation: Separate serum or plasma from cells within 2 hours of collection. Transport 2 mL serum or plasma. (Min: 1 mL)
Storage/Transport Temperature: **CRITICAL FROZEN**. **Separate specimens must be submitted when multiple tests are ordered.**
Remarks: Olanzapine shows slight interference with high levels of hemolysis in the sample. Noroxycodone causes an analytical interference and impacts the quantitation of Olanzapine.
Unacceptable Conditions: Whole blood. Gel separator tubes, light blue (citrate), or yellow (SPS or ACD solution). Hemolyzed samples.
Stability (collection to initiation of testing): After separation from cells: Ambient: Unacceptable; Refrigerated: Unacceptable; Frozen: 1 month

Reference Interval:
Effective November 15, 2021

Therapeutic Range:	20-80 ng/mL
Toxic:	Greater than or equal to 100 ng/mL

Interpretive Data:
Olanzapine is an antipsychotic drug indicated for the treatment of depression and bipolar disorder. The therapeutic range is based on serum, predose (trough) draw collection at steady-state concentration. Adverse effects may include dizziness, akathisia, postural hypotension, delirium, somnolence, neuroleptic malignant syndrome, hyperglycemia, and agitation.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.